Daily Newsletter

03 November 2023

Daily Newsletter

03 November 2023

Prelude and AbCellera jump on the ADC train with partnership

The companies will jointly develop up to five antibody-drug conjugates for treating cancer, with a focus on SMARCA degraders.

Phalguni Deswal November 02 2023

Prelude Therapeutics and AbCellera have partnered to jointly discover, develop, and commercialise antibody-drug conjugate candidates (ADCs) for cancer treatment.

The collaboration leverages Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinical development and AbCellera’s antibody discovery and development engine to generate novel precision ADCs.

ADCs have been identified as a key innovation area by GlobalData, with multiple companies investing in these therapies. The most recent company to join this trend was MSD (Merck & Co), which signed a collaboration agreement with Daiichi Sankyo to develop and market three ADCs last month.

GlobalData is the parent company of Pharmaceutical Technology.

Prelude will be responsible for the clinical development and global commercialisation, whilst AbCellera will lead the manufacturing activities for the ADCs. AbCellera will also have the option to co-promote the ADCs in the US, as per the 1 November press release.

AbCellera generated $10.1m in revenue from discovery activity in Q2 2023, as per the company’s financials. AbCellera has a market cap of $1.19bn.

In September, AbCellera expanded its partnership with Regeneron to discover up to eight therapeutic antibodies against the targets selected by the latter. The same month, the Canadian company also partnered with Incyte BioTherapeutics to develop and commercialise therapeutic cancer antibodies.

In June, AbCellera partnered with Confo Therapeutics to discover specific G protein-coupled receptor (GCPR) ligand-targeting antibody candidates.

Early R&D project coverage on Pharmaceutical Technology is supported by Mimotopes. Editorial content is independently produced and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Analyzing the key M&A trends in the Contract Manufacturing industry

Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close